5-HT2A receptor inverse agonists Archives

Acadia Resubmits Nuplazid for Expansion into Dementia-Related Psychosis

5-HT2A receptor inverse agonists, BioSpace, Delusions, FDA, Hallucinations, Neuropsychiatric Diseases, Parkinson’s Disease Psychosis, Primary Endpoints, R&D, Supplemental New Drug Application (sNDA)

Less than a year after a regulatory setback, Acadia Pharmaceuticals resubmitted the company’s supplemental New Drug Application for Nuplazid (pimavanserin) as a potential treatment for hallucinations and delusions associated with dementia-related psychosis.

February 17, 2022/by BioSpace

Acadia Halts Psychosis Clinical Trial Early for Nuplazid

5-HT2A receptor inverse agonists, Breakthrough Therapy Status, Clinical Trials, Dementia-Related Psychosis, FDA, Parkinson’s disease, Parkinson’s Disease Psychosis, Psychosis, R&D, Shares

Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.

September 9, 2019/by BioSpace